Caseware UK (AP4) 2024.0.164 2024.0.164 2024-05-312024-05-314The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.42023-06-01falseNo description of principal activityfalsetruefalse 12583364 2023-06-01 2024-05-31 12583364 2022-06-01 2023-05-31 12583364 2024-05-31 12583364 2023-05-31 12583364 c:Director1 2023-06-01 2024-05-31 12583364 d:Buildings d:ShortLeaseholdAssets 2023-06-01 2024-05-31 12583364 d:Buildings d:ShortLeaseholdAssets 2024-05-31 12583364 d:Buildings d:ShortLeaseholdAssets 2023-05-31 12583364 d:PlantMachinery 2023-06-01 2024-05-31 12583364 d:PlantMachinery 2024-05-31 12583364 d:PlantMachinery 2023-05-31 12583364 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-06-01 2024-05-31 12583364 d:MotorVehicles 2023-06-01 2024-05-31 12583364 d:FurnitureFittings 2023-06-01 2024-05-31 12583364 d:FurnitureFittings 2024-05-31 12583364 d:FurnitureFittings 2023-05-31 12583364 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-06-01 2024-05-31 12583364 d:ComputerEquipment 2023-06-01 2024-05-31 12583364 d:ComputerEquipment 2024-05-31 12583364 d:ComputerEquipment 2023-05-31 12583364 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-06-01 2024-05-31 12583364 d:OwnedOrFreeholdAssets 2023-06-01 2024-05-31 12583364 d:CurrentFinancialInstruments 2024-05-31 12583364 d:CurrentFinancialInstruments 2023-05-31 12583364 d:CurrentFinancialInstruments d:WithinOneYear 2024-05-31 12583364 d:CurrentFinancialInstruments d:WithinOneYear 2023-05-31 12583364 d:ShareCapital 2024-05-31 12583364 d:ShareCapital 2023-05-31 12583364 d:RetainedEarningsAccumulatedLosses 2024-05-31 12583364 d:RetainedEarningsAccumulatedLosses 2023-05-31 12583364 d:AcceleratedTaxDepreciationDeferredTax 2024-05-31 12583364 d:AcceleratedTaxDepreciationDeferredTax 2023-05-31 12583364 c:FRS102 2023-06-01 2024-05-31 12583364 c:AuditExempt-NoAccountantsReport 2023-06-01 2024-05-31 12583364 c:FullAccounts 2023-06-01 2024-05-31 12583364 c:PrivateLimitedCompanyLtd 2023-06-01 2024-05-31 12583364 e:PoundSterling 2023-06-01 2024-05-31 iso4217:GBP xbrli:pure

Registered number: 12583364









ULTRAFILTER MEDICAL LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MAY 2024

 
ULTRAFILTER MEDICAL LTD
REGISTERED NUMBER: 12583364

BALANCE SHEET
AS AT 31 MAY 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
218,735
819,036

  
218,735
819,036

Current assets
  

Stocks
  
14,563
14,563

Debtors: amounts falling due within one year
 5 
256,246
753,068

Cash at bank and in hand
 6 
26,481
60,954

  
297,290
828,585

Creditors: amounts falling due within one year
 7 
(35,357)
(877,961)

Net current assets/(liabilities)
  
 
 
261,933
 
 
(49,376)

Total assets less current liabilities
  
480,668
769,660

Provisions for liabilities
  

Deferred tax
 8 
(51,891)
(153,075)

  
 
 
(51,891)
 
 
(153,075)

Net assets
  
428,777
616,585


Capital and reserves
  

Called up share capital 
  
3
3

Profit and loss account
  
428,774
616,582

  
428,777
616,585


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.
 
Page 1

 
ULTRAFILTER MEDICAL LTD
REGISTERED NUMBER: 12583364
    
BALANCE SHEET (CONTINUED)
AS AT 31 MAY 2024


The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




D D Kronsbein
Director

Date: 1 August 2025

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
ULTRAFILTER MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

1.


General information

Ultrafilter Medical Ltd is a private company, limited by shares, registered in England and Wales. The address of the company's registered office is Unit 7 & 8 Alton Business Park, Alton Road, Ross-On-Wye, Herefordshire, HR9 5BP.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Page 3

 
ULTRAFILTER MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

2.Accounting policies (continued)

 
2.4

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.5

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
ULTRAFILTER MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

2.Accounting policies (continued)


2.6
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Short-term leasehold property
-
10%
on cost
Plant and machinery
-
25%
on reducing balance and 10% on cost
Motor vehicles
-
Fixtures and fittings
-
15%
on reducing balance
Computer equipment
-
33%
on reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 4 (2023 - 4).

Page 5

 
ULTRAFILTER MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

4.


Tangible fixed assets





Short-term leasehold property
Plant and machinery
Fixtures and fittings
Computer equipment
Total

£
£
£
£
£



Cost or valuation


At 1 June 2023
12,306
830,508
52,272
14,780
909,866


Additions
-
-
824
-
824


Disposals
-
(567,260)
-
-
(567,260)



At 31 May 2024

12,306
263,248
53,096
14,780
343,430



Depreciation


At 1 June 2023
3,692
61,916
16,241
8,982
90,831


Charge for the year on owned assets
1,231
26,816
5,528
1,913
35,488


Disposals
-
(1,624)
-
-
(1,624)



At 31 May 2024

4,923
87,108
21,769
10,895
124,695



Net book value



At 31 May 2024
7,383
176,140
31,327
3,885
218,735



At 31 May 2023
8,614
768,593
36,031
5,798
819,036


5.


Debtors

2024
2023
£
£


Trade debtors
42,562
229,252

Other debtors
194,296
510,345

Prepayments and accrued income
19,388
13,471

256,246
753,068


Page 6

 
ULTRAFILTER MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
26,481
60,954

26,481
60,954



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
5,658
660,550

Amounts owed to group undertakings
5,365
-

Corporation tax
2
182,851

Other taxation and social security
11,875
5,282

Other creditors
-
1,513

Accruals and deferred income
12,457
27,765

35,357
877,961



8.


Deferred taxation




2024


£






At beginning of year
(153,075)


Charged to profit or loss
101,184



At end of year
(51,891)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(51,891)
(153,075)

(51,891)
(153,075)

Page 7

 
ULTRAFILTER MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

9.


Related party transactions

At the balance sheet date, £69,691 (2023: £300,485) was owed to the company by the director.

 
Page 8